http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108718526-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate | 2017-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108718526-B |
| titleOfInvention | Crystal transformation of nintedanib salt and its preparation method |
| abstract | The solution of the present invention relates to (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl) of formula I Crystal modification of methyl methylene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate, wherein HX represents at least one acid component, preferably methanesulfonic acid, p- Toluenesulfonic acid, L-tartaric acid, maleic acid, acetic acid and phosphoric acid. Another solution also concerns processes for their preparation and their use in pharmaceutically acceptable compositions. Said crystalline form of nintedanib and manufactured salts for the preparation of (3Z)‑3‑{[(4‑{methyl[(4‑methylpiperazine‑1‑1) in any pharmaceutically acceptable salt form The use of methyl)acetyl]amino}phenyl)amino](phenyl)methylene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate is also an object of the present invention . |
| priorityDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.